Gamma Diagnostics awarded a grant to develop Antisense Oligonucleotides

Gamma Diagnostics has been awarded $277,710 USD by the National Institutes of Health to develop Antisense Oligonucleotides to Regulate Gamma Prime Fibrinogen Levels.

Gamma Diagnostics, Inc., has received a Phase I Small Business Technology Transfer (STTR) grant from the National Heart, Lung and Blood Institute of the National Institutes of health. This grant will allow Gamma Diagnostics to develop a drug to regulate the levels of gamma prime fibrinogen (GPF), which can reach very high levels in COVID-19 patients (doi: 10.1016/j.bcmd.2023.102746).

Their approach proposes to develop a drug that specifically affects GPF without changing the levels of the major form of fibrinogen, thereby preventing off-target effects that could lead to bleeding. Gamma Diagnostics has already developed a companion diagnostic test for GPF that can be used to monitor the effectiveness of the new drug. Together, this new drug and the companion diagnostic hold the promise of precision medicine for patients with high levels of GPF due to inflammatory diseases like COVID-19.